Kaposi sarcoma


Key articles

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Kaposi sarcoma [internet publication].Full text

ClinicalInfo.HIV.gov. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV. Sep 2022 [internet publication].Full text

Bower M, Palfreeman A, Alfa-Wali M, et al; British HIV Association. British HIV Association guidelines for HIV-associated malignancies 2014. HIV Med. 2014 Mar;15 (suppl 2):1-92.Full text  Abstract

ClinicalInfo.HIV.gov. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Sep 2022 [internet publication].Full text

World Health Organization. Guidelines on the treatment of skin and oral HIV-associated conditions in children and adults. Jan 2014 [internet publication].Full text

Reference articles

1. Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science. 1994 Dec 16;266(5192):1865-9. Abstract

2. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Kaposi sarcoma [internet publication].Full text

3. Lebbe C, Garbe C, Stratigos AJ, et al; European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organisation for Research and Treatment of Cancer (EORTC). Diagnosis and treatment of Kaposi's sarcoma: European consensus-based interdisciplinary guideline (EDF/EADO/EORTC). Eur J Cancer. 2019 Jun;114:117-27. Abstract

4. Cesarman E, Damania B, Krown SE, et al. Kaposi sarcoma. Nat Rev Dis Primers. 2019 Jan 31;5(1):9.Full text  Abstract

5. Esser S, Schöfer H, Hoffmann C, et al. S1 guidelines for the Kaposi sarcoma. J Dtsch Dermatol Ges. 2022 Jun;20(6):892-904.Full text  Abstract

6. American Cancer Society. Cancer facts & figures 2017 special section: rare cancers in adults. 2017 [internet publication].Full text

7. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021 May;71(3):209-49.Full text  Abstract

8. Engels EA, Pfeiffer RM, Goedert JJ, et al; HIV/AIDS Cancer Match Study. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS. 2006 Aug 1;20(12):1645-54. Abstract

9. Hernández-Ramírez RU, Shiels MS, Dubrow R, et al. Cancer risk in HIV-infected people in the USA from 1996 to 2012: a population-based, registry-linkage study. Lancet HIV. 2017 Nov;4(11):e495-504.Full text  Abstract

10. Motlhale M, Sitas F, Bradshaw D, et al. Epidemiology of Kaposi's sarcoma in sub-Saharan Africa. Cancer Epidemiol. 2022 Jun;78:102167.Full text  Abstract

11. Geddes M, Franceschi S, Barchielli A, et al. Kaposi's sarcoma in Italy before and after the AIDS epidemic. Br J Cancer. 1994 Feb;69(2):333-6. Abstract

12. Guttman-Yassky E, Bar-Chana M, Yukelson A, et al. Epidemiology of classic Kaposi's sarcoma in the Israeli Jewish population between 1960 and 1998. Br J Cancer. 2003 Nov 3;89(9):1657-60.Full text  Abstract

13. Moosa MR. Kaposi's sarcoma in kidney transplant recipients: a 23-year experience. QJM. 2005 Mar;98(3):205-14.Full text  Abstract

14. Serlin T, Ben Gal T, Kramer MR, et al. Trends in Kaposi's sarcoma morbidity: a retrospective cohort study of heart and lung transplant recipients. Acta Derm Venereol. 2021 Aug 25;101(8):adv00528.Full text  Abstract

15. Cahoon EK, Linet MS, Clarke CA, et al. Risk of Kaposi sarcoma after solid organ transplantation in the United States. Int J Cancer. 2018 Dec 1;143(11):2741-8.Full text  Abstract

16. Mbulaiteye SM, Engels EA. Kaposi's sarcoma risk among transplant recipients in the United States (1993-2003). Int J Cancer. 2006 Dec 1;119(11):2685-91.Full text  Abstract

17. Cook-Mozaffari P, Newton R, Beral V, et al. The geographical distribution of Kaposi's sarcoma and of lymphomas in Africa before the AIDS epidemic. Br J Cancer. 1998 Dec;78(11):1521-8. Abstract

18. Douglas JL, Gustin JK, Dezub BJ, et al. Kaposi's sarcoma: a model of both malignancy and chronic inflammation. Panminerva Medica. 2007 Sep;49(3):119-38. Abstract

19. Pantanowitz L, Früh K, Marconi S, et al. Pathology of rituximab-induced Kaposi sarcoma flare. BMC Clin Pathol. 2008 Jul 23;8:7.Full text  Abstract

20. Poizot-Martin I, Brégigeon S, Palich R, et al. Immune reconstitution inflammatory syndrome associated Kaposi sarcoma. Cancers (Basel). 2022 Feb 16;14(4):986.Full text  Abstract

21. Chabria S, Barakat L, Ogbuagu O. Steroid-exacerbated HIV-associated cutaneous Kaposi's sarcoma immune reconstitution inflammatory syndrome: 'Where a good intention turns bad'. Int J STD AIDS. 2016 Oct;27(11):1026-9. Abstract

22. Sullivan RJ, Pantanowitz L, Casper C, et al. HIV/AIDS: epidemiology, pathophysiology, and treatment of Kaposi sarcoma-associated herpesvirus disease: Kaposi sarcoma, primary effusion lymphoma, and multicentric Castleman disease. Clin Infect Dis. 2008 Nov 1;47(9):1209-15.Full text  Abstract

23. Gallafent JH, Buskin SE, De Turk PB, et al. Profile of patients with Kaposi's sarcoma in the era of highly active antiretroviral therapy. J Clin Oncol. 2005 Feb 20;23(6):1253-60.Full text  Abstract

24. Chao C, Jacobson LP, Jenkins FJ, et al. Recreational drug use and risk of Kaposi's sarcoma in HIV- and HHV-8-coinfected homosexual men. AIDS Res Hum Retroviruses. 2009 Feb;25(2):149-56.Full text  Abstract

25. Hiatt KM, Nelson AM, Lichy JH, et al. Classic Kaposi sarcoma in the United States over the last two decades: a clinicopathologic and molecular study of 438 non-HIV-related Kaposi sarcoma patients with comparison to HIV-related Kaposi sarcoma. Mod Pathol. 2008 May;21(5):572-82.Full text  Abstract

26. Mularoni A, Mikulska M, Giannella M, et al. International survey of human herpes virus 8 screening and management in solid organ transplantation. Transpl Infect Dis. 2021 Oct;23(5):e13698. Abstract

27. National Cancer Institute. Cancer causes and prevention: infectious agents. Kaposi sarcoma-associated herpesvirus (KSHV). Mar 2019 [internet publication].Full text

28. ClinicalInfo.HIV.gov. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV. Sep 2022 [internet publication].Full text

29. Bower M, Palfreeman A, Alfa-Wali M, et al; British HIV Association. British HIV Association guidelines for HIV-associated malignancies 2014. HIV Med. 2014 Mar;15 (suppl 2):1-92.Full text  Abstract

30. Radu O, Pantanowitz L. Kaposi sarcoma. Arch Pathol Lab Med. 2013 Feb;137(2):289-94.Full text  Abstract

31. Rosado FG, Itani DM, Coffin CM, et al. Utility of immunohistochemical staining with FLI1, D2-40, CD31, and CD34 in the diagnosis of acquired immunodeficiency syndrome-related and non-acquired immunodeficiency syndrome-related Kaposi sarcoma. Arch Pathol Lab Med. 2012 Mar;136(3):301-4.Full text  Abstract

32. Pitchenik AE, Fischl MA, Saldana MJ. Kaposi's sarcoma of the tracheobronchial tree. Clinical, bronchoscopic, and pathologic features. Chest. 1985 Jan;87(1):122-4. Abstract

33. Zibrak JD, Silvestri RC, Costello P, et al. Bronchoscopic and radiologic features of Kaposi's sarcoma involving the respiratory system. Chest. 1986 Oct;90(4):476-9. Abstract

34. Kodra A, Walczyszyn M, Grossman C, et al. Case report: pulmonary Kaposi sarcoma in a non-HIV patient. F1000Res. 2015 Oct 7;4:1013.Full text  Abstract

35. Caponetti G, Dezube BJ, Restrepo C, et al. Kaposi sarcoma of the musculoskeletal system: a review of 66 patients. Cancer. 2007 Mar 15;109(6):1040-52.Full text  Abstract

36. Ficarra G, Berson AM, Silverman S Jr, et al. Kaposi's sarcoma of the oral cavity: a study of 134 patients with a review of the pathogenesis, epidemiology, clinical aspects, and treatment. Oral Surg Oral Med Oral Pathol. 1988 Nov;66(5):543-50. Abstract

37. Glick M, Muzyka BC, Lurie D, et al. Oral manifestations associated with HIV-related disease as markers for immune suppression and AIDS. Oral Surg Oral Med Oral Pathol. 1994 Apr;77(4):344-9. Abstract

38. Dezube BJ, Pantanowitz L, Aboulafia DM. Management of AIDS-related Kaposi sarcoma: advances in target discovery and treatment. AIDS Read. 2004 May;14(5):236-8. Abstract

39. Morooka M, Ito K, Kubota K, et al. Whole-body 18F-fluorodeoxyglucose positron emission tomography/computed tomography images before and after chemotherapy for Kaposi sarcoma and highly active antiretrovirus therapy. Jpn J Radiol. 2010 Dec;28(10):759-62. Abstract

40. Pantanowitz L, Dezube BJ, Pinkus GS, et al. Histological characterization of regression in acquired immunodeficiency syndrome-related Kaposi's sarcoma. J Cutan Pathol. 2006 Apr;16(4):194-5. Abstract

41. Purgina B, Rao UN, Miettinen M, et al. AIDS-related EBV-associated smooth muscle tumors: a review of 64 published cases. Patholog Res Int. 2011 Mar 10;2011:561548.Full text  Abstract

42. Krown SE, Metroka C, Wernz JC. Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. J Clin Oncol. 1989 Sep;7(9):1201-7. Abstract

43. Krown SE, Testa MA, Huang J. AIDS-related Kaposi's sarcoma: prospective validation of the AIDS Clinical Trials Group staging classification. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol. 1997 Sep;15(9):3085-92. Abstract

44. Nasti G, Talamini R, Antinori A, et al. AIDS-related Kaposi's sarcoma: evaluation of potential new prognostic factors and assessment of the AIDS clinical trial group staging system in the HAART era - the Italian Cooperative Group on AIDS and Tumors and the Italian Cohort of Patients Naïve From Antiretrovirals. J Clin Oncol. 2003 Aug 1;21(15):2876-82. Abstract

45. Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod C, ed. Evaluation of chemotherapeutic agents. New York, NY: Columbia University Press; 1949:196.

46. Brambilla L, Boneschi V, Taglioni M, et al. Staging of classic Kaposi's sarcoma: a useful tool for therapeutic choices. Eur J Dermatol. 2003 Jan-Feb;13(1):83-6. Abstract

47. ClinicalInfo.HIV.gov. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Sep 2022 [internet publication].Full text

48. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach - second edition, 2016. Jun 2016 [internet publication].Full text

49. Gbabe OF, Okwundu CI, Dedicoat M, et al. Treatment of severe or progressive Kaposi's sarcoma in HIV-infected adults. Cochrane Database Syst Rev. 2014 Sep 1;(9):CD003256.Full text  Abstract

50. Shepherd FA, Maher E, Cardella C, et al. Treatment of Kaposi's sarcoma after solid organ transplantation. J Clin Oncol. 1997 Jun;15(6):2371-7. Abstract

51. Polizzotto MN, Uldrick TS, Wyvill KM, et al. Pomalidomide for symptomatic Kaposi's sarcoma in people with and without HIV infection: a phase I/II study. J Clin Oncol. 2016 Dec;34(34):4125-31.Full text  Abstract

52. Ramaswami R, Polizzotto MN, Lurain K, et al. Safety, activity, and long-term outcomes of pomalidomide in the treatment of Kaposi sarcoma among individuals with or without HIV infection. Clin Cancer Res. 2022 Mar 1;28(5):840-50.Full text  Abstract

53. Reid EG, Suazo A, Lensing SY, et al; AIDS Malignancy Consortium (AMC). Pilot trial AMC-063: safety and efficacy of bortezomib in AIDS-associated Kaposi sarcoma. Clin Cancer Res. 2020 Feb 1;26(3):558-65.Full text  Abstract

54. Fortino S, Santoro M, Iuliano E, et al. Treatment of Kaposi's sarcoma (KS) with nab-paclitaxel. Paper presented at: XVIII National Congress of Medical Oncology. 28-30 Oct 2016. Rome, Italy. Session S: miscellanea. Abstract S63. Ann Oncol. 2016 Sep;27(Suppl 4):iv124.Full text

55. Pourcher V, Desnoyer A, Assoumou L, et al. Phase II trial of lenalidomide in HIV-infected patients with previously treated Kaposi's sarcoma: results of the ANRS 154 Lenakap Trial. AIDS Res Hum Retroviruses. 2017 Jan;33(1):1-10. Abstract

56. Schwartsmann G, Sprinz E, Kromfield M, et al. Clinical and pharmacokinetic study of oral etoposide in patients with AIDS-related Kaposi's sarcoma with no prior exposure to cytotoxic therapy. J Clin Oncol. 1997 May;15(5):2118-24. Abstract

57. Tas F, Sen F, Keskin S, et al. Oral etoposide as first-line therapy in the treatment of patients with advanced classic Kaposi's sarcoma (CKS): a single-arm trial (oral etoposide in CKS). J Eur Acad Dermatol Venereol. 2013 Jun;27(6):789-92. Abstract

58. Hosseinipour MC, Kang M, Krown SE, et al; A5264/AMC-067 REACT-KS Team. As-needed vs immediate etoposide chemotherapy in combination with antiretroviral therapy for mild-to-moderate AIDS-associated Kaposi sarcoma in resource-limited settings: A5264/AMC-067 Randomized Clinical Trial. Clin Infect Dis. 2018 Jul 2;67(2):251-60.Full text  Abstract

59. Caccialanza M, Marca S, Piccinno R, et al. Radiotherapy of classic and human immunodeficiency virus-related Kaposi's sarcoma: results in 1482 lesions. J Eur Acad Dermatol Venereol. 2008 Mar;22(3):297-302. Abstract

60. Stein ME, Spencer D, Ruff P, et al. Endemic African Kaposi sarcoma: clinical and therapeutic implications. 10-year experience in the Johannesburg Hospital (1980-1990). Oncology. 1994 Jan-Feb;51(1):63-9. Abstract

61. Wang X, Bao Z, Zhang X, et al. Effectiveness and safety of PD-1/PD-L1 inhibitors in the treatment of solid tumors: a systematic review and meta-analysis. Oncotarget. 2017 May 31;8(35):59901-14.Full text  Abstract

62. ClinicalTrials.gov. Phase II multicentric study of pembrolizumab in classic or endemic Kaposi's sarcoma (KAPKEY). NCT03469804. Oct 2019 [internet publication].Full text

63. Delyon J, Biard L, Renaud M, et al. PD-1 blockade with pembrolizumab in classic or endemic Kaposi's sarcoma: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2022 Apr;23(4):491-500. Abstract

64. Zer A, Icht O, Yosef L, et al. Phase II single-arm study of nivolumab and ipilimumab (Nivo/Ipi) in previously treated classical Kaposi sarcoma (cKS). Ann Oncol. 2022 Jul;33(7):720-7. Abstract

65. Ferioli M, Galuppi A, Buwenge M, et al. Electrochemotherapy in Kaposi sarcoma: A systematic review. Mol Clin Oncol. 2021 Apr;14(4):64.Full text  Abstract

66. ClinicalTrials.gov. sEphB4-HSA in treating patients with Kaposi sarcoma. NCT02799485. Jun 2022 [internet publication].Full text

67. Little RF, Pluda JM, Wyvill KM, et al. Activity of subcutaneous interleukin-12 in AIDS-related Kaposi sarcoma. Blood. 2006 Jun 15;107(12):4650-7.Full text  Abstract

68. Little RF, Aleman K, Kumar P, et al. Phase 2 study of pegylated liposomal doxorubicin in combination with interleukin-12 for AIDS-related Kaposi sarcoma. Blood. 2007 Dec 15;110(13):4165-71.Full text  Abstract

69. ClinicalTrials.gov. NHS-IL12 monotherapy and in combination with M7824 in advanced Kaposi sarcoma. NCT04303117. Jul 2022 [internet publication].Full text

70. ClinicalTrials.gov. Nelfinavir mesylate in treating patients with Kaposi sarcoma. NCT03077451. Sep 2022 [internet publication].Full text

71. National Cancer Institute. Kaposi sarcoma treatment (PDQ). Sep 2022 [internet publication].Full text

72. World Health Organization. Guidelines on the treatment of skin and oral HIV-associated conditions in children and adults. Jan 2014 [internet publication].Full text

73. Lacouture ME, Sibaud V, Gerber PA, et al. Prevention and management of dermatological toxicities related to anticancer agents: ESMO clinical practice guidelines. Ann Oncol. 2021 Feb;32(2):157-70.Full text  Abstract

74. De Boer C, Niyonzima N, Orem J, et al. Prognosis and delay of diagnosis among Kaposi's sarcoma patients in Uganda: a cross-sectional study. Infect Agent Cancer. 2014 May 20;9:17.Full text  Abstract

75. Feller L, Masipa J, Wood N, et al. The prognostic significance of facial lymphoedema in HIV-seropositive subjects with Kaposi sarcoma. AIDS Res Ther. 2008 Jan 29;5:2.Full text  Abstract

76. Pantanowitz L, Dezube BJ. AIDS-associated Kaposi sarcoma of the larynx. AIDS Read. 2006 Apr;16(4):194-5. Abstract

77. Bower M, Nelson M, Young AM, et al. Immune reconstitution inflammatory syndrome associated with Kaposi's sarcoma. J Clin Oncol. 2005 Aug 1;23(22):5224-8.Full text  Abstract

78. Dumic I, Radovanovic M, Igandan O, et al. A fatal case of Kaposi sarcoma immune reconstitution syndrome (KS-IRIS) complicated by Kaposi sarcoma inflammatory cytokine syndrome (KICS) or multicentric Castleman disease (MCD): a case report and review. Am J Case Rep. 2020 Dec 3;21:e926433.Full text  Abstract

Use of this content is subject to our disclaimer